Cargando…
SARS-CoV-2 BNT162b2 vaccine–induced humoral response and reactogenicity in individuals with prior COVID-19 disease
BACKGROUND: Most individuals with prior COVID-19 disease manifest long-term protective immune responses against reinfection. Accordingly, we tested the hypothesis that humoral immune and reactogenicity responses to a SARS-CoV-2 mRNA vaccine differ in individuals with and without prior COVID-19 disea...
Autores principales: | Kelsen, Steven G., Braverman, Alan S., Aksoy, Mark O., Hayman, Jacob A., Patel, Puja S., Rajput, Charu, Zhao, Huaqing, Fisher, Susan G., Ruggieri, Michael R., Gentile, Nina T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876462/ https://www.ncbi.nlm.nih.gov/pubmed/35019861 http://dx.doi.org/10.1172/jci.insight.155889 |
Ejemplares similares
-
Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
por: Bauernfeind, Stilla, et al.
Publicado: (2021) -
Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty(®))
por: Held, Jürgen, et al.
Publicado: (2021) -
Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability
por: Graydon, Elizabeth K., et al.
Publicado: (2023) -
BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity
por: Vizcarra, Pilar, et al.
Publicado: (2021) -
2349. Natural Killer Cells and BNT162b2 mRNA Vaccine Reactogenicity and Durability
por: Graydon, Elizabeth K, et al.
Publicado: (2023)